Evidence map›Paper›PMID 41526435›Full record

ArticleNPJ precision oncology2026

KRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors.

Iris Z Uras, Marija V Trkulja, Abdelrahman K A A Salama, Jaqueline Horvath, Khushi Asnani, Christoph Trenk, Stefan Kubicek, Martin Bilban, Herwig P Moll, Emilio Casanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Iris Z UrasInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria. iris.uras@meduniwien.ac.at.
Marija V Trkulja *Institute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Abdelrahman K A A Salama *Institute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Jaqueline HorvathInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Khushi AsnaniInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Christoph TrenkInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Stefan KubicekCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Martin BilbanDepartment of Laboratory Medicine & Core Facilities, Medical University of Vienna, Vienna, Austria.
Herwig P MollInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.
Emilio CasanovaInstitute of Pharmacology, Center of Physiology and Pharmacology & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.

Funding

Austrian Science Fund 10.55776/P36728Austrian Science Fund 10.55776/PAT5733623
6 · The paper itself

Abstract

KRAS mutations are prevalent in lung adenocarcinoma (LUAD). Although KRAS-targeted therapies such as KRAS-G12C inhibitor sotorasib are now clinically available, their durability is limited by rapid resistance development, underscoring the need for novel strategies. Through high-throughput drug screening, we identified Aurora kinase (AURK) inhibitors as potent enhancers of afatinib efficacy in KRAS mutant LUAD models. ERBB/AURK co-inhibition synergized to suppress cell viability, clonogenicity, and tumor growth, mediated by induction of apoptosis, G

Identifiers

PMID41526435
PMCPMC12796156

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.